Profound Medical (PROF) Stock Forecast, Price Target & Predictions
PROF Stock Forecast
Profound Medical stock forecast is as follows: an average price target of $15.17 (represents a 117.34% upside from PROF’s last price of $6.98) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PROF Price Target
The average price target for Profound Medical (PROF) is $15.17 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $12.00. This represents a potential 117.34% upside from PROF's last price of $6.98.
PROF Analyst Ratings
According to 2 Wall Street analysts, Profound Medical's rating consensus is 'Buy'. The analyst rating breakdown for PROF stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Profound Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 02, 2024 | Ben Haynor | Loop Capital Markets | $17.00 | $8.03 | 111.84% | 143.55% |
| Jul 23, 2024 | Ben Haynor | Lake Street | $16.50 | $10.28 | 60.47% | 136.39% |
| Jul 15, 2024 | Rick Wise | Stifel Nicolaus | $12.00 | $9.15 | 31.15% | 71.92% |
The latest Profound Medical stock forecast, released on Dec 02, 2024 by Ben Haynor from Loop Capital Markets, set a price target of $17.00, which represents a 111.84% increase from the stock price at the time of the forecast ($8.03), and a 143.55% increase from PROF last price ($6.98).
Profound Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $17.00 | $17.00 | $15.17 |
| Last Closing Price | $6.98 | $6.98 | $6.98 |
| Upside/Downside | 143.55% | 143.55% | 117.34% |
In the current month, the average price target of Profound Medical stock is $17.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 143.55% increase as opposed to Profound Medical's last price of $6.98. This month's average price target is down 0.00% compared to last quarter, and up 12.06% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | Lake Street | Buy | Buy | Hold |
| Jan 06, 2023 | Lake Street | Buy | Buy | Hold |
| Feb 22, 2022 | Raymond James | Outperform | Downgrade |
Profound Medical's last stock rating was published by Lake Street on Dec 02, 2024. The company gave PROF a "Buy" rating, the same as its previous rate.
Profound Medical Financial Forecast
Profound Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.86M | $1.26M | $2.04M | $2.02M | $1.36M | $998.00K | $2.54M | $2.63M | $711.00K | $2.85M | $2.23M | $1.04M | $1.10M | $2.17M | $515.35K |
| Avg Forecast | $22.90M | $21.00M | $18.00M | $16.40M | $9.73M | $7.93M | $5.67M | $4.80M | $4.22M | $3.00M | $2.64M | $2.44M | $1.97M | $2.20M | $2.13M | $2.12M | $2.67M | $2.41M | $2.02M | $1.76M | $2.79M | $3.57M | $2.20M | $2.48M | $2.31M | $1.71M | $737.22K | $892.29K | $2.08M | $1.16M |
| High Forecast | $28.69M | $26.31M | $22.55M | $20.54M | $12.19M | $9.94M | $7.10M | $6.24M | $4.27M | $3.76M | $3.31M | $3.05M | $2.47M | $2.75M | $2.67M | $2.65M | $3.35M | $2.41M | $2.02M | $1.76M | $2.79M | $3.57M | $2.20M | $2.48M | $2.31M | $1.71M | $737.22K | $892.29K | $2.08M | $1.16M |
| Low Forecast | $18.51M | $16.97M | $14.55M | $13.25M | $7.87M | $6.41M | $4.58M | $3.36M | $4.18M | $2.43M | $2.13M | $1.97M | $1.59M | $1.78M | $1.72M | $1.71M | $2.16M | $2.41M | $2.02M | $1.76M | $2.79M | $3.57M | $2.20M | $2.48M | $2.31M | $1.71M | $737.22K | $892.29K | $2.08M | $1.16M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.47% | 0.84% | 1.00% | 0.78% | 0.36% | 0.71% | 1.20% | 0.29% | 1.24% | 1.30% | 1.41% | 1.23% | 1.04% | 0.44% |
Profound Medical's average Quarter revenue forecast for Jun 23 based on 2 analysts is $2.13M, with a low forecast of $1.72M, and a high forecast of $2.67M. PROF's average Quarter revenue forecast represents a 14.69% increase compared to the company's last Quarter revenue of $1.86M (Mar 23).
Profound Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.22M | $-5.52M | $-7.61M | $-7.04M | $-6.74M | $-10.05M | $-5.43M | $-6.49M | $-7.03M | $-7.35M | $-5.47M | $-4.82M | $-1.63M | $-3.35M | $-4.08M |
| Avg Forecast | $-22.90M | $-21.00M | $-18.00M | $-16.40M | $-9.73M | $-7.93M | $-5.67M | $-4.80M | $-4.22M | $-3.00M | $-2.64M | $-2.44M | $-1.97M | $-2.20M | $-2.13M | $-2.12M | $-2.67M | $-2.41M | $-2.02M | $-8.23M | $-2.79M | $-3.57M | $-2.20M | $-4.42M | $-2.31M | $-1.71M | $-737.22K | $-2.02M | $-2.08M | $-1.16M |
| High Forecast | $-18.51M | $-16.97M | $-14.55M | $-13.25M | $-7.87M | $-6.41M | $-4.58M | $-3.36M | $-4.18M | $-2.43M | $-2.13M | $-1.97M | $-1.59M | $-1.78M | $-1.72M | $-1.71M | $-2.16M | $-2.41M | $-2.02M | $-6.58M | $-2.79M | $-3.57M | $-2.20M | $-3.54M | $-2.31M | $-1.71M | $-737.22K | $-1.62M | $-2.08M | $-1.16M |
| Low Forecast | $-28.69M | $-26.31M | $-22.55M | $-20.54M | $-12.19M | $-9.94M | $-7.10M | $-6.24M | $-4.27M | $-3.76M | $-3.31M | $-3.05M | $-2.47M | $-2.75M | $-2.67M | $-2.65M | $-3.35M | $-2.41M | $-2.02M | $-9.87M | $-2.79M | $-3.57M | $-2.20M | $-5.31M | $-2.31M | $-1.71M | $-737.22K | $-2.43M | $-2.08M | $-1.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.94% | 2.06% | 3.15% | 3.49% | 0.82% | 3.60% | 1.52% | 2.96% | 1.59% | 3.18% | 3.20% | 6.54% | 0.80% | 1.61% | 3.51% |
undefined analysts predict PROF's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Profound Medical's previous annual EBITDA (undefined) of $NaN.
Profound Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.74M | $-9.53M | $-5.00M | $-5.93M | $-8.21M | $-10.16M | $-6.00M | $-7.04M | $-7.50M | $-7.36M | $-6.08M | $-5.38M | $-2.54M | $-4.10M | $-4.74M |
| Avg Forecast | - | - | - | - | $-6.91M | $-7.68M | $-8.55M | $-9.32M | $-10.52M | $-9.99M | $-9.49M | $-9.95M | $-10.20M | $-11.30M | $-11.47M | $-11.78M | $-12.34M | $-12.70M | $-12.47M | $-8.79M | $-11.06M | $-8.99M | $-8.87M | $-4.72M | $-9.32M | $-7.96M | $-7.56M | $-3.16M | $-14.14M | $-12.03M |
| High Forecast | - | - | - | - | $-5.19M | $-5.76M | $-6.42M | $-8.68M | $-9.17M | $-7.50M | $-7.13M | $-7.47M | $-8.38M | $-8.48M | $-8.61M | $-8.84M | $-9.27M | $-12.70M | $-12.47M | $-7.03M | $-11.06M | $-8.99M | $-8.87M | $-3.78M | $-9.32M | $-7.96M | $-7.56M | $-2.53M | $-14.14M | $-12.03M |
| Low Forecast | - | - | - | - | $-9.18M | $-10.20M | $-11.36M | $-9.64M | $-11.86M | $-13.27M | $-12.61M | $-13.22M | $-11.66M | $-15.01M | $-15.23M | $-15.64M | $-16.40M | $-12.70M | $-12.47M | $-10.55M | $-11.06M | $-8.99M | $-8.87M | $-5.67M | $-9.32M | $-7.96M | $-7.56M | $-3.79M | $-14.14M | $-12.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.57% | 0.77% | 0.39% | 0.48% | 0.93% | 0.92% | 0.67% | 0.79% | 1.59% | 0.79% | 0.76% | 0.71% | 0.80% | 0.29% | 0.39% |
Profound Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PROF's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Profound Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.21M | $3.77M | $4.59M | $5.03M | $4.55M | $5.53M | $4.54M | $4.18M | $3.72M | $3.45M | $3.03M | $2.67M | $3.04M | $2.99M | $2.21M |
| Avg Forecast | $52.58M | $48.21M | $41.33M | $37.65M | $22.35M | $18.21M | $13.01M | $11.02M | $9.70M | $6.90M | $6.06M | $5.60M | $4.52M | $5.05M | $4.90M | $4.86M | $6.14M | $5.54M | $4.63M | $4.03M | $6.40M | $8.19M | $5.04M | $2.34M | $5.30M | $3.93M | $1.69M | $2.05M | $4.78M | $2.67M |
| High Forecast | $65.86M | $60.39M | $51.77M | $47.17M | $27.99M | $22.82M | $16.30M | $14.33M | $9.81M | $8.64M | $7.59M | $7.01M | $5.67M | $6.32M | $6.14M | $6.09M | $7.69M | $5.54M | $4.63M | $4.03M | $6.40M | $8.19M | $5.04M | $2.81M | $5.30M | $3.93M | $1.69M | $2.05M | $4.78M | $2.67M |
| Low Forecast | $42.49M | $38.97M | $33.40M | $30.43M | $18.06M | $14.72M | $10.51M | $7.71M | $9.59M | $5.58M | $4.90M | $4.52M | $3.66M | $4.08M | $3.96M | $3.93M | $4.96M | $5.54M | $4.63M | $4.03M | $6.40M | $8.19M | $5.04M | $1.87M | $5.30M | $3.93M | $1.69M | $2.05M | $4.78M | $2.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.61% | 0.83% | 1.09% | 1.13% | 0.86% | 0.55% | 0.83% | 1.59% | 0.65% | 0.77% | 1.58% | 1.48% | 0.62% | 0.83% |
Profound Medical's average Quarter SG&A projection for Jun 23 is $4.90M, based on 2 Wall Street analysts, with a range of $3.96M to $6.14M. The forecast indicates a 16.31% rise compared to PROF last annual SG&A of $4.21M (Mar 23).
Profound Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 5 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 7 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.32 | $-0.46 | $-0.24 | $-0.29 | $-0.40 | $-0.50 | $-0.29 | $-0.35 | $-0.37 | $-0.39 | $-0.32 | $-0.34 | $-0.18 | $-0.28 | $-0.43 |
| Avg Forecast | - | - | - | - | $-0.28 | $-0.31 | $-0.35 | $-0.38 | $-0.43 | $-0.41 | $-0.39 | $-0.40 | $-0.41 | $-0.46 | $-0.47 | $-0.48 | $-0.50 | $-0.52 | $-0.51 | $-0.56 | $-0.45 | $-0.37 | $-0.36 | $-0.34 | $-0.38 | $-0.33 | $-0.31 | $-0.38 | $-0.58 | $-0.49 |
| High Forecast | - | - | - | - | $-0.21 | $-0.23 | $-0.26 | $-0.35 | $-0.37 | $-0.30 | $-0.29 | $-0.30 | $-0.34 | $-0.34 | $-0.35 | $-0.36 | $-0.38 | $-0.52 | $-0.51 | $-0.56 | $-0.45 | $-0.37 | $-0.36 | $-0.34 | $-0.38 | $-0.33 | $-0.31 | $-0.38 | $-0.58 | $-0.49 |
| Low Forecast | - | - | - | - | $-0.37 | $-0.41 | $-0.46 | $-0.39 | $-0.48 | $-0.54 | $-0.51 | $-0.54 | $-0.47 | $-0.61 | $-0.62 | $-0.63 | $-0.67 | $-0.52 | $-0.51 | $-0.56 | $-0.45 | $-0.37 | $-0.36 | $-0.34 | $-0.38 | $-0.33 | $-0.31 | $-0.38 | $-0.58 | $-0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 0.92% | 0.46% | 0.57% | 0.72% | 1.11% | 0.79% | 0.96% | 1.07% | 1.03% | 0.99% | 1.09% | 0.47% | 0.48% | 0.88% |
According to undefined Wall Street analysts, Profound Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PROF previous annual EPS of $NaN (undefined).
Profound Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROF | Profound Medical | $6.98 | $15.17 | 117.34% | Buy |
| SGHT | Sight Sciences | $3.55 | $7.50 | 111.27% | Hold |
| LUNG | Pulmonx | $6.16 | $13.00 | 111.04% | Buy |
| KIDS | OrthoPediatrics | $22.58 | $39.50 | 74.93% | Buy |
| NVRO | Nevro | $3.97 | $5.84 | 47.10% | Hold |
| LIVN | LivaNova | $46.75 | $68.25 | 45.99% | Buy |
| SIBN | SI-BONE | $13.27 | $18.50 | 39.41% | Buy |
| OFIX | Orthofix Medical | $17.34 | $24.00 | 38.41% | |
| NPCE | NeuroPace | $11.14 | $15.00 | 34.65% | Buy |
| ITGR | Integer | $134.75 | $153.50 | 13.91% | Buy |
| FNA | Paragon 28 | $10.27 | $11.50 | 11.98% | Buy |
| IRMD | IRadimed | $54.21 | $60.00 | 10.68% | Buy |
| CVRX | CVRx | $12.90 | $14.25 | 10.47% | Buy |
| AORT | Artivion | $28.55 | $30.75 | 7.71% | Buy |
| SRDX | Surmodics | $39.68 | $39.50 | -0.45% | Buy |